Comprehensive Molecular Characterization of Pediatric Treatment-Induced High-Grade Glioma: A Distinct Entity Despite Disparate Etiologies with Defining Molecular Characteristics and Potential Therapeutic Targets
John DeSisto,John T. Lucas,Ke Xu,Andrew Donson,Tong Lin,Bridget Sanford,Gang Wu,Quynh T. Tran,Dale Hedges,Chih-Yang Hsu,Gregory T. Armstrong,Michael Arnold,Smita Bhatia,Patrick Flannery,Rakeb Lemma,Lakotah Hardie,Ulrich Schüller,Lindsey M. Hoffman,Kathleen Dorris,Jean Mulcahy Levy,Todd C. Hankinson,Michael Handler,Arthur Liu,Nicholas Foreman,Rajeev Vibhakar,Kenneth Jones,Sariah Allen,Jinghui Zhang,Suzanne J. Baker,Thomas E. Merchant,Brent A. Orr,Adam L. Green
DOI: https://doi.org/10.1101/809772
2019-01-01
Abstract:Treatment-induced high-grade gliomas (TIHGGs) are an incurable late complication of cranial radiation therapy or combined radiation/chemotherapy used to treat pediatric cancer. We assembled a cohort of 33 TIHGGs from multiple institutions. The primary antecedent malignancies were medulloblastoma, acute lymphoblastic leukemia, astrocytoma, and ependymoma. We performed methylation profiling, RNA-seq, and genomic sequencing (whole-genome or whole-exome) on TIHGG samples. Methylation profiling revealed that TIHGGs cluster primarily with the pediatric receptor tyrosine kinase I subtype (26/31 samples). Common TIHGG copy-number alterations include Chromosome (Ch.) 1p loss/1q gain, Ch. 4 loss, Ch. 6q loss, and Ch. 13 and Ch. 14 loss; focal alterations include PDGFRA and CDK4 gain and loss of CDKN2A and BCOR . Relative to de novo pediatric high-grade glioma (pHGG), BCOR loss (p=0.004) and CDKN2A loss (p=0.005) were significantly increased. Transcriptomic analysis identified two distinct TIHGG subgroups, one with a lesser mutation burden (0.12 mut/Mb), Ch. 1p loss/1q gain (5/6 samples), and stem cell characteristics, and one with a greater mutation burden (1.08 mut/Mb, p<0.0002), depletion of DNA repair pathways, and inflammatory characteristics. We observed increased chromothripsis in TIHGG versus pHGG (67% vs. 31%, p=0.036), which was associated with extrachromosomal circular DNA-mediated amplification of PDGFRA and CDK4 . In vitro drug screening in one primary, patient-derived TIHGG cell line from each expression subgroup identified microtubule inhibitors/stabilizers, DNA-damaging agents, MEK inhibition, and, in the inflammatory subgroup, proteasome inhibitors as potentially effective therapies. This study provides a comprehensive molecular profile of TIHGG, including mechanistic insights to TIHGG oncogenesis, and identifies potentially effective therapeutic modalities for further investigation.